Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Astria Therapeutics, Inc.CATB · Entity 68888 | CMO; SVP Clinical Development | February 12, 2020 | February 14, 2020 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | CMO | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Astria Therapeutics, Inc.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 · Expires 2030-02-11 | Direct | 60,000 |
Reported balance
After 2020-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-12 · Grant · Acquired 60,000 · Balance 60,000 F1: This option was granted on February 12. 2020 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 12. 2020 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 12, 2020 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 65,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 65,000 · Balance 65,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2019 Filed Feb 15, 2019 08:41 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001179110-19-001941 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 13, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0333% per month. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 16:13 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001179110-18-011282 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-09-06 F1 · derivative.exercise_date: This option was granted on September 7, 2018 and is subject to vesting over a two year period, with 50% of the shares vesting on the first anniversary of September 7, 2018 and the remainder vesting over the ensuing year at a rate of 4.1667% per month. Read SEC document |
| February 08, 2018 Filed Feb 9, 2018 16:02 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001179110-18-001882 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: This option was granted on February 8, 2018 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 8, 2018 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 16:05 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001179110-17-002158 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2017 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of the date of grant and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 16:17 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001179110-16-029555 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-09-07 F1 · derivative.exercise_date: This option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of the date of grant and the remainder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
| September 08, 2016 Filed Sep 13, 2016 17:24 UTC Amendment | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001179110-16-029617 · edgar.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO; SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2026-09-07 F1 · derivative.exercise_price: This Form 4/A is being filed to correct the stated Conversion or Exercise Price of Derivative Security. The correct Exercise Price of the Derivative Security is $4.31 and was previously stated as $4.30. F2 · derivative.exercise_date: The option was granted on September 8, 2016 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 8, 2016 and the reminder vesting over the ensuing three years at a rate of 2.0833% per month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.